Phase II study of sorafenib in children with recurrent or progressive low-grade astrocytomas

Activation of the RAS-RAF-MEK-ERK signaling pathway is thought to be the key driver of pediatric low-grade astrocytoma (PLGA) growth. Sorafenib is a multikinase inhibitor targeting BRAF, VEGFR, PDGFR, and c-kit. This multicenter phase II study was conducted to determine the response rate to sorafeni...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Neuro-oncology (Charlottesville, Va.) Va.), 2014-10, Vol.16 (10), p.1408-1416
Hauptverfasser:	Karajannis, Matthias A, Legault, Geneviève, Fisher, Michael J, Milla, Sarah S, Cohen, Kenneth J, Wisoff, Jeffrey H, Harter, David H, Goldberg, Judith D, Hochman, Tsivia, Merkelson, Amanda, Bloom, Michael C, Sievert, Angela J, Resnick, Adam C, Dhall, Girish, Jones, David T W, Korshunov, Andrey, Pfister, Stefan M, Eberhart, Charles G, Zagzag, David, Allen, Jeffrey C
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Animals Antineoplastic Agents - therapeutic use Astrocytoma - drug therapy Astrocytoma - mortality Astrocytoma - pathology Brain Neoplasms - drug therapy Brain Neoplasms - mortality Brain Neoplasms - pathology Child, Preschool Female Humans Kaplan-Meier Estimate Magnetic Resonance Imaging Male MAP Kinase Signaling System - drug effects Mice Niacinamide - administration & dosage Niacinamide - analogs & derivatives Niacinamide - therapeutic use NIH 3T3 Cells Pediatric Neuro-Oncology Phenylurea Compounds - administration & dosage Phenylurea Compounds - therapeutic use Protein Kinase Inhibitors - administration & dosage Protein Kinase Inhibitors - therapeutic use Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!